• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Immune environment may dictate durability of response to CAR-T for multiple myeloma

by | Aug 31, 2022 | Uncategorized

Prolonged responses to chimeric antigen receptor T-cell therapy for advanced multiple myeloma may depend on the composition of the patient’s post-treatment immune microenvironment, results from a retrospective study showed.Patients with prolonged PFS after B-cell...

‘Mounting Evidence’ Suggests Exposure to Environmental Toxins Plays a Role in Onset of Myeloma, Says Expert

by | Aug 29, 2022 | Uncategorized

Source: Cure Today articles Firefighters and recovery workers exposed to the aftermath of 9/11 in New York City had a higher occurrence of MGUS, a condition which may progress to myeloma, according to recent research. Read More

Addition of Empliciti to Combination Regimen Continues to Show Benefit in Previously Treated Multiple Myeloma

by | Aug 29, 2022 | Uncategorized

Source: Cure Today articles Long-term follow-up shows that treatment with Empliciti plus pomalidomide and dexamethasone continues to significantly increase survival rates in patients with relapsed or refractory multiple myeloma, a persistent cancer affecting white...

Abecma Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma

by | Aug 10, 2022 | Uncategorized

Source: Cure Today articles Data from a clinical trial demonstrate a “clear clinical benefit” of using a CAR-T cell therapy in patients with multiple myeloma, according to the drugs manufacturer. Read More

Abecma significantly extends survival among patients with advanced multiple myeloma

by | Aug 10, 2022 | Uncategorized

Idecabtagene vicleucel extended PFS compared with standard regimens for adults with advanced multiple myeloma, according to topline data released by the agent’s manufacturer.Idecabtagene vicleucel (Abecma; Bristol Myers Squibb, 2seventy bio) — also known as ide-cel —...

High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments

by | Aug 10, 2022 | Uncategorized

Clin Lymphoma Myeloma Leuk. 2022 Jul 16:S2152-2650(22)00220-8. doi: 10.1016/j.clml.2022.07.001. Online ahead of print. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a malignancy of plasma cells that arises from premalignant Monoclonal Gammopathy of Undetermined...
« Older Entries
Next Entries »

Recent Content

  • A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
  • Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
  • Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT